Narrative medicine in metastatic prostate cancer reveals ways to improve patient awareness & quality of care

Author:

De Vincentis Giuseppe1,Monari Fabio2,Baldari Sergio3,Salgarello Matteo4,Frantellizzi Viviana1,Salvi Elisabetta2,Reale Luigi5,Napolitano Silvia5,Conti Giario67,Cortesi Enrico8

Affiliation:

1. Department of Radiological Sciences, Oncology & Anatomo-Pathology, Sapienza - University of Rome, Rome, Italy

2. UO Metabolic Radiation Unit Bologna, Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola-Malpighi, Emilia-Romagna, Italy

3. Department of Biomedical Sciences & Morphological & Functional Images, Università degli Studi di Messina, Messina, Italy

4. Division of Nuclear Medicine, Sacro Cuore – Don Calabria Hospital, Negraro (VR), Italy

5. ISTUD Foundation, Healthcare Area, Milan, Italy

6. Department of Urology, Sant'Anna Hospital, Como, Italy

7. Segretario Nazionale della Società Italiana di Urologia Oncologica (SIUrO), Bologna, Italy

8. Medical Oncology, Policlinico Umberto I, Sapienza, University of Rome, Rome, Italy

Abstract

Aim: To describe the journey of patients with metastatic castration-resistant prostate cancer (mCRPC) in treatment with radium-223. Methods: A multiperspective analysis was performed using narrative medicine in four Italian centers. Results: The substantial impact of mCRPC on quality of life through all phases of the disease was described. After an initial lack of awareness of the disease or denial of its effects, symptoms of pain, fatigue and side effects often led to sadness, fear and loneliness. The majority underwent radium-223 therapy positively, restoring their quality of life and routine activities. Conclusion: Using narrative medicine, the importance of a patient-centered approach in the pathway of care for patients with mCRPC through all the stages of the disease was highlighted.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Reference39 articles.

1. Cancer statistics, 2017

2. Linee guida Aiom. Carcinoma della prostata (2017). www.aiom.it/C_Common/Download.asp?file=/$Site$/files/doc/LG/2017_LGAIOM_Prostata.pdf.

3. European Medicines Agency. Xofigo, INN- radium-223 dichloride. www.ema.europa.eu/documents/product-information/xofigo-epar-product-information_en.pdf

4. Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3